Head and Neck Cancer | Norton Healthcare

Indication: Head and Neck Cancer

NRG-HN004: Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Locoregionally Advanced Head and Neck Cancer with a Contraindication to Cisplatin

Sub-indication: Locoregionally Advanced H&N Cancer

Line of Therapy: 1st or 2nd line

Drug Study

Principal Investigator: Aaron Spalding, M.D.
Norton Cancer Institute

Sponsor: NRG Oncology

Learn more at ClinicalTrials.gov

Email for more information: Head&Neck-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.